Welcome

Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. To date, three medicines discovered at Exelixis have received regulatory approval to treat different types of cancer. We are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients in need of new treatment options.

Stock

EXEL
Jun 21 2017 4:00pm EDT
24.02 +1.74
0 SHARES

Exelixis Annual Report 2016

Teamwork is a constant across drug development and patient care. Learn about the company’s performance in 2016, and how the Exelixis team and the broader oncology community come together in their collective effort to help patients.

Learn More
Download PDF